High Growth Tech Stocks To Watch In The None Exchange

As global markets have been buoyed by a rise in U.S. stock indexes nearing record highs and growth stocks outperforming value shares, small-cap stocks have lagged behind, evidenced by the Russell 2000 Index trailing the S&P 500 Index. In this context of heightened inflation expectations and volatile treasury yields, identifying high-growth tech stocks that can capitalize on innovation and market trends becomes crucial for investors looking to navigate these dynamic conditions effectively.

Top 10 High Growth Tech Companies

Name	Revenue Growth	Earnings Growth	Growth Rating
Seojin SystemLtd	35.41%	39.86%	★★★★★★
Clinuvel Pharmaceuticals	21.39%	26.17%	★★★★★★
Yggdrazil Group	30.20%	87.10%	★★★★★★
eWeLLLtd	25.35%	25.09%	★★★★★★
Pharma Mar	23.77%	45.40%	★★★★★★
Xspray Pharma	127.78%	104.91%	★★★★★★
Mental Health TechnologiesLtd	21.91%	92.81%	★★★★★★
JNTC	24.99%	104.40%	★★★★★★
Dmall	29.53%	88.37%	★★★★★★
Delton Technology (Guangzhou)	20.25%	29.52%	★★★★★★

Click here to see the full list of 1204 stocks from our High Growth Tech and AI Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Kingsoft (SEHK:3888)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Kingsoft Corporation Limited operates in the entertainment and office software and services sectors across Mainland China, Hong Kong, and internationally, with a market cap of HK$57.00 billion.

Operations: The company generates revenue primarily through its online games and office software and services segments, with each contributing approximately CN¥4.93 billion and CN¥4.91 billion respectively.

Kingsoft, a player in the competitive tech landscape, has demonstrated robust financial performance with its earnings soaring by 296.8% over the past year, outpacing the Entertainment industry's growth of 10.1%. This surge is underpinned by an aggressive R&D investment strategy that not only fuels innovation but also aligns with projected annual revenue and earnings growth rates of 14.1% and 23.8%, respectively—figures that eclipse broader market averages in Hong Kong. Despite some concerns over significant insider selling in recent months and a forecasted low return on equity of 8.7% in three years, Kingsoft’s commitment to research and development positions it well within a sector where technological advancements rapidly dictate market dynamics. The company's ability to maintain positive free cash flow amidst these expenditures further underscores its operational efficacy and potential for sustained growth amidst evolving industry demands.

• Dive into the specifics of Kingsoft here with our thorough health report.

• Gain insights into Kingsoft's past trends and performance with our Past report.

Shenzhen Kangtai Biological Products (SZSE:300601)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Shenzhen Kangtai Biological Products Co., Ltd. is a company engaged in the research, development, production, and sale of vaccines with a market capitalization of approximately CN¥17.54 billion.

Operations: The company's primary revenue stream comes from biochemical products, generating approximately CN¥3.03 billion.

Shenzhen Kangtai Biological Products has shown a remarkable financial trajectory, with revenue and earnings growth outpacing the broader Chinese market at 20.3% and 37.5% annually. This growth is significantly bolstered by strategic R&D investments, which have not only enhanced its competitive edge in the biotech industry but also maintained a positive free cash flow despite substantial one-off gains of CN¥154.4M impacting financial results last year. Recent leadership changes and strategic corporate actions underscore a proactive approach to governance and operational agility, positioning the company favorably for future industry demands and innovations.

• Click here and access our complete health analysis report to understand the dynamics of Shenzhen Kangtai Biological Products.

• Explore historical data to track Shenzhen Kangtai Biological Products' performance over time in our Past section.

Cybozu (TSE:4776)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Cybozu, Inc. develops, sells, and operates groupware solutions in Japan with a market capitalization of ¥142.78 billion.

Operations: Cybozu focuses on developing and operating groupware solutions in Japan. The company generates revenue primarily through the sale of its software products and services.

Cybozu has demonstrated robust growth with a 13.2% annual increase in revenue, outpacing the Japanese market's average of 4.2%. This growth is complemented by an impressive earnings surge of 42.9% over the past year, significantly higher than the software industry's average of 14.2%. Strategic share repurchases have also been a focus; from October to December 2024, Cybozu repurchased approximately 1.41 million shares for ¥2.93 billion, reflecting confidence in its financial health and future prospects. The company's commitment to innovation is evident in its R&D investments that support sustained growth and competitive advantage in the evolving tech landscape.

• Get an in-depth perspective on Cybozu's performance by reading our health report here.

• Understand Cybozu's track record by examining our Past report.

Taking Advantage

• Delve into our full catalog of 1204 High Growth Tech and AI Stocks here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com